Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
Crossref DOI link: https://doi.org/10.1007/s00213-016-4450-3
Published Online: 2016-11-02
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Durgam, Suresh
Greenberg, William M.
Li, Dayong
Lu, Kaifeng
Laszlovszky, Istvan
Nemeth, Gyorgy
Migliore, Raffaele
Volk, Stephen
Funding for this research was provided by:
Gedeon Richter Plc.
Forest Laboratories, LLC, an Allergan affiliate
License valid from 2016-11-02